Mount Airy Dialysis Center Of Wake Forest University is a medicare approved dialysis facility center in Mount Airy, North Carolina and it has 27 dialysis stations. It is located in Surry county at 1280 Newsome Street, Mount Airy, NC, 27030. You can reach out to the office of Mount Airy Dialysis Center Of Wake Forest University at (336) 789-4090. This dialysis clinic is managed and/or owned by Wake Forest University. Mount Airy Dialysis Center Of Wake Forest University has the following ownership type - Non-Profit. It was first certified by medicare in July, 1990. The medicare id for this facility is 342551 and it accepts patients under medicare ESRD program.
| Name | Mount Airy Dialysis Center Of Wake Forest University |
|---|---|
| Location | 1280 Newsome Street, Mount Airy, North Carolina |
| No. of Dialysis Stations | 27 |
| Medicare ID | 342551 |
| Managed By | Wake Forest University |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 1280 Newsome Street, Mount Airy, North Carolina, 27030 | |
| (336) 789-4090 | |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
| NPI Number | 1982681904 |
| Organization Name | Mt. Airy Dialysis Center |
| Doing Business As | Mt. Airy Dialysis Center Of Wake Forest University |
| Address | 1280 Newsome St Mt Airy, North Carolina, 27030 |
| Phone Number | (336) 789-4090 |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 73% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 17% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 10% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 68% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 14% |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 66% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 20% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 14% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 77% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 12% |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 86% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 14% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 79% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 14% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 7% | 12% |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 58 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 21 |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 78 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 713 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
| Adult patients getting regular peritoneal dialysis at the center | 30 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 231 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 94 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Mount Airy Dialysis Center Of Wake Forest University with elevated calcium levels.
| Patients with hypercalcemia | 112 |
| Hypercalcemia patient months | 1031 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 114 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 26 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 29 |
| Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 74 |
| Patient months included in arterial venous fistula and catheter summaries | 651 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 67 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 21 |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 96 |
| Hospitalization Rate in facility | 158.6 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 271.5 |
| Hospitalization Rate: Lower Confidence Limit | 100.5 |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at Mount Airy Dialysis Center Of Wake Forest University were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 25.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.2 |
| Readmission Rate: Lower Confidence Limit | 16.3 |
News Archive
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.
Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream.
› Verified 6 days ago